Prophylactic cranial irradiation for patients with SCLC-a new perspective in the immunotherapy era
Levy, A. Rusthoven, C. G. Brown, P. D. Le Péchoux, C. Faivre-Finn, Corinne
Levy, A.
Rusthoven, C. G.
Brown, P. D.
Le Péchoux, C.
Faivre-Finn, Corinne
Citations
Altmetric:
Abstract
Prophylactic cranial irradiation (PCI) has long been used for SCLC to reduce the risk of brain metastases and potentially improve overall survival. Nevertheless, recent immunotherapy trials have provided limited data on its impact, as few patients were treated with PCI. The ADRIATIC trial reported improved outcomes with consolidation immunotherapy in limited-stage SCLC, and PCI was a stratification factor. Notably, patients receiving PCI in both arms had better outcomes than those who did not. Ongoing studies, such as EORTC-1901 PRIMALung (NCT04790253) and SWOG 1827-MAVERICK (NCT04155034), are further investigating PCI's role in the era of immunotherapy, highlighting its potential importance in evolving treatment strategies.
Description
Date
2024
Publisher
Collections
Keywords
Type
Article
Citation
Levy A, Rusthoven CG, Brown PD, Le Péchoux C, Faivre-Finn C. Prophylactic Cranial Irradiation for Patients With SCLC-A New Perspective in the Immunotherapy Era. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2024 Nov 15. PubMed PMID: 39551470. Epub 2024/11/18. eng.